Mark Lebwohl on Muck Rack

Mark Lebwohl

New York
As seen in: Wiley Online Library, Oxford Academic, MDPI, JAMA (The Journal of the American Medical Association), JAMA Dermatology, JAMA Network, JAMA: Journal of the American Medical Association, Medscape, The New England Journal of Medicine, Newsday and
Lord Of The Rings expert, Gamer, Chef, Videographer, Martial Artist, Knight of Columbus.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mark

Contact Mark, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Q&A: Implications of Ixekizumab, Tirzepatide Data for Psoriasis and PsA, With Mark Lebwohl, MD

|
By Mark Lebwohl
| consultantlive.com
New data from the phase 3b TOGETHER-PsO trial continue to spotlight the growing intersection between psoriasis and obesity management.1 These data, showing the improvements in skin clearance and weight reduction with combined ixekizumab (Taltz) and tirzepatide (Zepbound) versus ixekizumab alone, were touched on in a recent interview with Mark Lebwohl, MD, of the Icahn School of Medicine at Mount Sinai.2 The analysis, looking at adults with moderate-to-severe plaque psoriasis and obesity or...
Open in Who Shared View Duplicates (2) Issue with article?

Phase 3b Data on Ixekizumab, Tirzepatide for Psoriasis and Overweight, With Mark Lebwohl, MD

|
By Mark Lebwohl
| consultantlive.com
Published on: This interview highlights recent phase 3b data from the TOGETHER-PsO trial on ixekizumab and tirzepatide for psoriasis and obesity or overweight.
Open in Who Shared View Duplicates (2) Issue with article?

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity : A Phase 3b Randomized Clinical Trial

|
By Mark Lebwohl
| JAMA Network
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial Supplement 1. Supplement 2. Statistical analysis plan Supplement 3. eAppendix 1. Eligibility criteria eAppendix 2. Tirzepatide dose modification eAppendix 3. Concomitant medications eAppendix 4. Assessments of dermatological outcomes eAppendix 5. Statistical analyses eFigure 1. TOGETHER-PsO trial design eFigure 2. Primary and key secondary end points at Week 36 eFigure 3.
Open in Who Shared Issue with article?
See all 142 licensed articles (278 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Mark

Contact Mark, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified